Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin

Metabolism, Excretion, and Pharmacokinetics of [14 C]-Cefiderocol (S-649266), a Siderophore Cephalosporin, in Healthy Subjects Following Intravenous Administration

(2019) Shiro Miyazaki et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effect of Cefiderocol, a Siderophore Cephalosporin, on QT/QTc Interval in Healthy Adult Subjects

(2019) Carlos Sanabria et al.   CLINICAL THERAPEUTICS

In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria

(2019) Yoshinori Yamano   CLINICAL INFECTIOUS DISEASES

Pathogen-focused Clinical Development to Address Unmet Medical Need: Cefiderocol Targeting Carbapenem Resistance

(2019) Roger Echols et al.   CLINICAL INFECTIOUS DISEASES

Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis

(2018) Nao Kawaguchi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects

(2018) Yutaka Saisho et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters

(2018) Takayuki Katsube et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials

(2018) Konstantinos Z Vardakas et al.   LANCET INFECTIOUS DISEASES

Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

(2018) Evelina Tacconelli et al.   LANCET INFECTIOUS DISEASES

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial

(2018) Simon Portsmouth et al.   LANCET INFECTIOUS DISEASES

1366. In Vitro and In Vivo Activity of Cefiderocol against Stenotrophomonas maltophilia Clinical Isolates

(2018) Akinobu Ito et al.   Open Forum Infectious Diseases

Good Correlation of Cefiderocol Between In Vivo Efficacy Murine Thigh/Lung Infection Models and MIC Determined in Iron-Depleted Conditions

(2017) Yoshinori Yamano et al.   Open Forum Infectious Diseases

In Vivo Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Murine Urinary Tract Infection Models

(2017) Shuhei Matsumoto et al.   Open Forum Infectious Diseases

248S-649266, a Novel Siderophore Cephalosporin: Efficacy against Klebsiella pneumoniae producing NDM-1 or KPC in rat lung infection model with recreated humanized exposure profile of 2 gram dose with 1 hour and 3 hours infusion

(2017) Masakatsu Tsuji et al.   Open Forum Infectious Diseases

Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, for Dose Adjustment Based on Renal Function

(2016) Takayuki Katsube et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment

(2016) Takayuki Katsube et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae

(2016) Elizabeth A. Neuner et al.   Virulence

In VitroAntimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains

(2015) Naoki Kohira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitroantimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria

(2015) Akinobu Ito et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Implications of Augmented Renal Clearance on Drug Dosing in Critically Ill Patients: A Focus on Antibiotics

(2015) Athena L. V. Hobbs et al.   PHARMACOTHERAPY

Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions

(2014) Jason A Roberts et al.   LANCET INFECTIOUS DISEASES

Broad-spectrum β-lactams in obese non-critically ill patients

(2014) M Hites et al.   Nutrition & Diabetes

Membrane transporters in drug development

(2010)   NATURE REVIEWS DRUG DISCOVERY

Augmented Renal Clearance

(2009) Andrew A. Udy et al.   CLINICAL PHARMACOKINETICS